Buffington Mohr McNeal Has $640,000 Holdings in Edwards Lifesciences Co. (NYSE:EW)

Buffington Mohr McNeal increased its position in Edwards Lifesciences Co. (NYSE:EW) by 6.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 6,700 shares of the medical research company’s stock after purchasing an additional 400 shares during the quarter. Buffington Mohr McNeal’s holdings in Edwards Lifesciences were worth $640,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. DSM Capital Partners LLC bought a new position in shares of Edwards Lifesciences during the 4th quarter worth approximately $28,000. Turtle Creek Wealth Advisors LLC bought a new position in shares of Edwards Lifesciences during the fourth quarter valued at $34,000. Riverview Trust Co acquired a new stake in shares of Edwards Lifesciences in the 1st quarter valued at $34,000. Pingora Partners LLC bought a new stake in shares of Edwards Lifesciences in the 4th quarter worth about $38,000. Finally, SRS Capital Advisors Inc. increased its position in shares of Edwards Lifesciences by 292.6% during the 3rd quarter. SRS Capital Advisors Inc. now owns 636 shares of the medical research company’s stock worth $44,000 after purchasing an additional 474 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $87.54, for a total value of $437,700.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at $4,108,777.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,250 shares of the company’s stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $85.80, for a total value of $622,050.00. Following the transaction, the chief financial officer now directly owns 19,074 shares in the company, valued at $1,636,549.20. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $87.54, for a total transaction of $437,700.00. Following the sale, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $4,108,777.44. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 119,849 shares of company stock valued at $10,579,038. 1.27% of the stock is owned by insiders.

Edwards Lifesciences Stock Up 1.1 %

NYSE:EW traded up $0.98 during trading hours on Tuesday, reaching $91.23. 1,908,916 shares of the stock were exchanged, compared to its average volume of 3,459,121. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.75 and a quick ratio of 2.67. Edwards Lifesciences Co. has a twelve month low of $60.57 and a twelve month high of $96.12. The stock has a market cap of $54.98 billion, a PE ratio of 39.32, a PEG ratio of 3.38 and a beta of 1.11. The firm has a 50 day moving average of $87.92 and a 200 day moving average of $85.46.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.64 by $0.02. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. The business had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.58 billion. On average, equities analysts expect that Edwards Lifesciences Co. will post 2.77 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Stifel Nicolaus upped their price objective on shares of Edwards Lifesciences from $83.00 to $85.00 and gave the stock a “hold” rating in a research note on Friday, April 26th. OTR Global upgraded shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research report on Tuesday, March 26th. Deutsche Bank Aktiengesellschaft upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and upped their price objective for the company from $86.00 to $103.00 in a report on Tuesday, May 14th. Barclays raised their target price on Edwards Lifesciences from $100.00 to $101.00 and gave the stock an “overweight” rating in a report on Tuesday, May 7th. Finally, Mizuho upped their price target on Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a research note on Thursday, April 11th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $95.18.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.